Edgewell Personal Care Co has a consensus price target of $44.38 based on the ratings of 8 analysts. The high is $53 issued by Canaccord Genuity on May 9, 2024. The low is $33 issued by Morgan Stanley on November 10, 2023. The 3 most-recent analyst ratings were released by Barclays, Barclays, and Canaccord Genuity on July 19, 2024, May 10, 2024, and May 9, 2024, respectively. With an average price target of $44.67 between Barclays, Barclays, and Canaccord Genuity, there's an implied 12.06% upside for Edgewell Personal Care Co from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/19/2024 | Buy Now | 2.86% | Barclays | Lauren Lieberman | $40 → $41 | Maintains | Equal-Weight | Get Alert |
05/10/2024 | Buy Now | 0.35% | Barclays | Lauren Lieberman | $37 → $40 | Maintains | Equal-Weight | Get Alert |
05/09/2024 | Buy Now | 32.97% | Canaccord Genuity | Susan Anderson | $52 → $53 | Maintains | Buy | Get Alert |
04/12/2024 | Buy Now | -7.18% | Barclays | Lauren Lieberman | $39 → $37 | Maintains | Equal-Weight | Get Alert |
02/08/2024 | Buy Now | 7.88% | Wells Fargo | Chris Carey | $40 → $43 | Maintains | Overweight | Get Alert |
02/08/2024 | Buy Now | -2.16% | Barclays | Lauren Lieberman | → $39 | Upgrade | Underweight → Equal-Weight | Get Alert |
01/16/2024 | Buy Now | -12.19% | Barclays | Lauren Lieberman | $32 → $35 | Maintains | Underweight | Get Alert |
11/10/2023 | Buy Now | -17.21% | Morgan Stanley | Dara Mohsenian | $38 → $33 | Maintains | Underweight | Get Alert |
10/12/2023 | Buy Now | -19.72% | Barclays | Lauren Lieberman | $37 → $32 | Maintains | Underweight | Get Alert |
08/07/2023 | Buy Now | -7.18% | Barclays | Lauren Lieberman | $36 → $37 | Maintains | Underweight | Get Alert |
07/20/2023 | Buy Now | -9.68% | Barclays | Lauren Lieberman | $40 → $36 | Maintains | Underweight | Get Alert |
05/12/2023 | Buy Now | 0.35% | Barclays | Lauren Lieberman | $38 → $40 | Maintains | Underweight | Get Alert |
05/10/2023 | Buy Now | 32.97% | Canaccord Genuity | Susan Anderson | $52 → $53 | Maintains | Buy | Get Alert |
05/10/2023 | Buy Now | -4.67% | Morgan Stanley | Dara Mohsenian | $35 → $38 | Maintains | Underweight | Get Alert |
04/05/2023 | Buy Now | 17.91% | UBS | Peter Grom | → $47 | Initiates | → Neutral | Get Alert |
02/10/2023 | Buy Now | -4.67% | Barclays | Lauren Lieberman | $37 → $38 | Maintains | Underweight | Get Alert |
02/09/2023 | Buy Now | 32.97% | RBC Capital | Nik Modi | → $53 | Reiterates | → Outperform | Get Alert |
02/09/2023 | Buy Now | 30.46% | Canaccord Genuity | Susan Anderson | $48 → $52 | Maintains | Buy | Get Alert |
11/17/2022 | Buy Now | 20.42% | Canaccord Genuity | Susan Anderson | → $48 | Initiates | → Buy | Get Alert |
11/14/2022 | Buy Now | -12.19% | Barclays | Lauren Lieberman | $31 → $35 | Maintains | Underweight | Get Alert |
11/11/2022 | Buy Now | -12.19% | Morgan Stanley | Dara Mohsenian | $36 → $35 | Maintains | Underweight | Get Alert |
11/11/2022 | Buy Now | 10.39% | Wells Fargo | Chris Carey | $43 → $44 | Maintains | Overweight | Get Alert |
11/07/2022 | Buy Now | 7.88% | Wells Fargo | Roger Read | $46 → $43 | Maintains | Overweight | Get Alert |
10/26/2022 | Buy Now | 5.37% | Goldman Sachs | Jason English | $47 → $42 | Downgrade | Buy → Neutral | Get Alert |
10/17/2022 | Buy Now | -9.68% | Morgan Stanley | Dara Mohsenian | $40 → $36 | Downgrade | Equal-Weight → Underweight | Get Alert |
08/08/2022 | Buy Now | -17.21% | Barclays | Lauren Lieberman | $29 → $33 | Maintains | Underweight | Get Alert |
08/03/2022 | Buy Now | 10.39% | Wells Fargo | Chris Carey | $39 → $44 | Maintains | Overweight | Get Alert |
05/12/2022 | Buy Now | -27.25% | Barclays | Lauren Lieberman | $34 → $29 | Maintains | Underweight | Get Alert |
05/11/2022 | Buy Now | -2.16% | Morgan Stanley | Dara Mohsenian | $43 → $39 | Maintains | Equal-Weight | Get Alert |
05/11/2022 | Buy Now | -2.16% | Wells Fargo | Chris Carey | $43 → $39 | Maintains | Overweight | Get Alert |
02/10/2022 | Buy Now | 7.88% | Morgan Stanley | Dara Mohsenian | $46 → $43 | Maintains | Equal-Weight | Get Alert |
02/09/2022 | Buy Now | 17.91% | Wells Fargo | Chris Carey | $55 → $47 | Maintains | Overweight | Get Alert |
09/28/2021 | Buy Now | -7.18% | Wells Fargo | Chris Carey | — | Maintains | Underweight | Get Alert |
08/06/2021 | Buy Now | 30.46% | RBC Capital | Nik Modi | — | Maintains | Outperform | Get Alert |
The latest price target for Edgewell Personal Care (NYSE:EPC) was reported by Barclays on July 19, 2024. The analyst firm set a price target for $41.00 expecting EPC to rise to within 12 months (a possible 2.86% upside). 10 analyst firms have reported ratings in the last year.
The latest analyst rating for Edgewell Personal Care (NYSE:EPC) was provided by Barclays, and Edgewell Personal Care maintained their equal-weight rating.
The last upgrade for Edgewell Personal Care Co happened on February 8, 2024 when Barclays raised their price target to $39. Barclays previously had an underweight for Edgewell Personal Care Co.
The last downgrade for Edgewell Personal Care Co happened on October 26, 2022 when Goldman Sachs changed their price target from $47 to $42 for Edgewell Personal Care Co.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Edgewell Personal Care, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Edgewell Personal Care was filed on July 19, 2024 so you should expect the next rating to be made available sometime around July 19, 2025.
While ratings are subjective and will change, the latest Edgewell Personal Care (EPC) rating was a maintained with a price target of $40.00 to $41.00. The current price Edgewell Personal Care (EPC) is trading at is $39.86, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.